Short- and long-term clinical outcomes of nintedanib therapy in
IPF patients with different phenotypes: A retrospective
registry-based study

J 2024

Short- and long-term clinical outcomes of nintedanib therapy in IPF patients with different phenotypes: A retrospective registry-based study

KOZIAR VASAKOVA, Martina, Jakub GREGOR, Nesrin MOGULKOC, Mordechai R KRAMER, Katarzyna LEWANDOWSKA et. al.

Základní údaje

Originální název

Short- and long-term clinical outcomes of nintedanib therapy in IPF patients with different phenotypes: A retrospective registry-based study

Autoři

KOZIAR VASAKOVA, Martina (203 Česká republika), Jakub GREGOR (203 Česká republika, domácí), Nesrin MOGULKOC, Mordechai R KRAMER, Katarzyna LEWANDOWSKA, Martina STERCLOVA (203 Česká republika), Veronika MUELLER, Robert SLIVKA, Michael STUDNICKA (203 Česká republika), Martina PLACKOVA (203 Česká republika), Monika ZURKOVA (203 Česká republika), Jasna TEKAVEC-TRKANJEC, Martina DOUBKOVÁ (203 Česká republika, domácí) a Petra OVESNÁ (203 Česká republika, domácí)

Vydání

RESPIRATORY MEDICINE, LONDON, W B SAUNDERS CO LTD, 2024, 0954-6111

Další údaje

Jazyk

angličtina

Typ výsledku

Článek v odborném periodiku

Obor

30203 Respiratory systems

Stát vydavatele

Velká Británie a Severní Irsko

Utajení

není předmětem státního či obchodního tajemství

Odkazy

URL

Impakt faktor

Impact factor: 3.500 v roce 2023

Kód RIV

RIV/00216224:14110/24:00137305

Organizační jednotka

Lékařská fakulta

DOI

http://dx.doi.org/10.1016/j.rmed.2024.107791

UT WoS

001318539800001

EID Scopus

2-s2.0-85203511425

Klíčová slova anglicky

Idiopathic pulmonary fibrosis; Treatment; Survival; Lung

Štítky

14110215, 14119612, rivok

Příznaky

Mezinárodní význam, Recenzováno

Změněno: 8. 10. 2024 14:22, Mgr. Tereza Miškechová

Anotace

V originále

Background: There is a lack of data on the long-term effect of nintedanib on survival in specific groups of idiopathic pulmonary fibrosis (IPF) patients with different phenotypes. We investigated the outcomes of nintedanib therapy in an observational study of a large multicentre real-world cohort of IPF patients with various initial characteristics. Methods: The analysis included IPF patients treated with nintedanib (NIN) and IPF patients not receiving anti- fibrotic treatment (NAF) enrolled for the EMPIRE registry in 2015-2020. The patients were stratified according to their initial FVC predicted, dyspnoea, UIP pattern and age. All-cause mortality and annual rate of FVC decline were the main endpoints. Cox proportional hazards model for survival assessment and linear mixed-effects model for FVC decline modelling were used. Results: A total of 869 NIN patients and 691 NAF patients were eligible for the analysis. The annual FVC decline rate was significantly different (adjusted values-0.053 l/yr vs-0.122 l/yr; p = 0.001). The adjusted hazard ratio (HR) for mortality was 0.40 (95 % CI 0.3 to 0.53, p < 0.001). The most significant effect of nintedanib was demonstrated in patients with impaired lung function, i.e., with an FVC predicted to be less than 80 % and a NYHA II to IV. Nintedanib therapy also reduced the difference in survival between men and women. Conclusions: Modelling confirmed that NIN therapy reduced differences in OS between patients with better and worse initial conditions and prognosis. Our results indicate that NIN is particularly beneficial for patients with advanced IPF and more severe phenotypes. Trial registration: EMPIRE was registered as a non-interventional post-registration study at the State Institute for Drug Control of the Czech Republic under ID 1412080000 on December 8, 2014.

Citovat

KOZIAR VASAKOVA, Martina, Jakub GREGOR, Nesrin MOGULKOC, Mordechai R KRAMER, Katarzyna LEWANDOWSKA, Martina STERCLOVA, Veronika MUELLER, Robert SLIVKA, Michael STUDNICKA, Martina PLACKOVA, Monika ZURKOVA, Jasna TEKAVEC-TRKANJEC, Martina DOUBKOVÁ a Petra OVESNÁ. Short- and long-term clinical outcomes of nintedanib therapy in IPF patients with different phenotypes: A retrospective registry-based study. RESPIRATORY MEDICINE. LONDON: W B SAUNDERS CO LTD, 2024, roč. 234, November-December 2024, s. 1-8. ISSN 0954-6111. Dostupné z: https://dx.doi.org/10.1016/j.rmed.2024.107791.

@article{2441521,
   author = {Koziar Vasakova, Martina and Gregor, Jakub and Mogulkoc, Nesrin and Kramer, Mordechai R and Lewandowska, Katarzyna and Sterclova, Martina and Mueller, Veronika and Slivka, Robert and Studnicka, Michael and Plackova, Martina and Zurkova, Monika and TekavecandTrkanjec, Jasna and Doubková, Martina and Ovesná, Petra},
   article_location = {LONDON},
   article_number = {November-December 2024},
   doi = {http://dx.doi.org/10.1016/j.rmed.2024.107791},
   keywords = {Idiopathic pulmonary fibrosis; Treatment; Survival; Lung},
   language = {eng},
   issn = {0954-6111},
   journal = {RESPIRATORY MEDICINE},
   title = {Short- and long-term clinical outcomes of nintedanib therapy in IPF patients with different phenotypes: A retrospective registry-based study},
   url = {https://www.sciencedirect.com/science/article/pii/S095461112400266X?via%3Dihub},
   volume = {234},
   year = {2024}
}

TY  - JOUR
ID  - 2441521
AU  - Koziar Vasakova, Martina - Gregor, Jakub - Mogulkoc, Nesrin - Kramer, Mordechai R - Lewandowska, Katarzyna - Sterclova, Martina - Mueller, Veronika - Slivka, Robert - Studnicka, Michael - Plackova, Martina - Zurkova, Monika - Tekavec-Trkanjec, Jasna - Doubková, Martina - Ovesná, Petra
PY  - 2024
TI  - Short- and long-term clinical outcomes of nintedanib therapy in IPF patients with different phenotypes: A retrospective registry-based study
JF  - RESPIRATORY MEDICINE
VL  - 234
IS  - November-December 2024
SP  - 1-8
EP  - 1-8
PB  - W B SAUNDERS CO LTD
SN  - 09546111
KW  - Idiopathic pulmonary fibrosis
KW  - Treatment
KW  - Survival
KW  - Lung
UR  - https://www.sciencedirect.com/science/article/pii/S095461112400266X?via%3Dihub
N2  - Background: There is a lack of data on the long-term effect of nintedanib on survival in specific groups of idiopathic pulmonary fibrosis (IPF) patients with different phenotypes. We investigated the outcomes of nintedanib therapy in an observational study of a large multicentre real-world cohort of IPF patients with various initial characteristics. Methods: The analysis included IPF patients treated with nintedanib (NIN) and IPF patients not receiving anti- fibrotic treatment (NAF) enrolled for the EMPIRE registry in 2015-2020. The patients were stratified according to their initial FVC predicted, dyspnoea, UIP pattern and age. All-cause mortality and annual rate of FVC decline were the main endpoints. Cox proportional hazards model for survival assessment and linear mixed-effects model for FVC decline modelling were used. Results: A total of 869 NIN patients and 691 NAF patients were eligible for the analysis. The annual FVC decline rate was significantly different (adjusted values-0.053 l/yr vs-0.122 l/yr; p = 0.001). The adjusted hazard ratio (HR) for mortality was 0.40 (95 % CI 0.3 to 0.53, p < 0.001). The most significant effect of nintedanib was demonstrated in patients with impaired lung function, i.e., with an FVC predicted to be less than 80 % and a NYHA II to IV. Nintedanib therapy also reduced the difference in survival between men and women. Conclusions: Modelling confirmed that NIN therapy reduced differences in OS between patients with better and worse initial conditions and prognosis. Our results indicate that NIN is particularly beneficial for patients with advanced IPF and more severe phenotypes. Trial registration: EMPIRE was registered as a non-interventional post-registration study at the State Institute for Drug Control of the Czech Republic under ID 1412080000 on December 8, 2014.
ER  -

KOZIAR VASAKOVA, Martina, Jakub GREGOR, Nesrin MOGULKOC, Mordechai R KRAMER, Katarzyna LEWANDOWSKA, Martina STERCLOVA, Veronika MUELLER, Robert SLIVKA, Michael STUDNICKA, Martina PLACKOVA, Monika ZURKOVA, Jasna TEKAVEC-TRKANJEC, Martina DOUBKOVÁ a Petra OVESNÁ. Short- and long-term clinical outcomes of nintedanib therapy in IPF patients with different phenotypes: A retrospective registry-based study. \textit{RESPIRATORY MEDICINE}. LONDON: W B SAUNDERS CO LTD, 2024, roč.~234, November-December 2024, s.~1-8. ISSN~0954-6111. Dostupné z: https://dx.doi.org/10.1016/j.rmed.2024.107791.

Přehled o publikaci